Vaccine News and Research

Latest Vaccine News and Research

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A.

18 Aug 2014

61% of U.S. adults unaware of the importance of high dose flu vaccine in flu prevention for older adults

A new survey from CVS/pharmacy released today found that three in five U.S. adults (61 percent) are unaware of the importance of the high dose flu vaccine in flu prevention for adults 65 years and older.

16 Aug 2014

WHO taps UTMB to lead emerging infectious disease vaccine efforts

The world experts on vaccine development at the University of Texas Medical Branch at Galveston have received an international designation acknowledging their unique niche in a sphere where research, government regulation and big pharma often collide.

16 Aug 2014

Medical advisory panel recommends new pneumonia vaccine for seniors

The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates report that insurers are balking at paying for a costly drug to treat hepatitis C if the patients are in drug treatment programs.

15 Aug 2014

Ebola virus disease poses new challenges for healthcare professionals

The outbreak of Ebola virus disease that has claimed more than 1,000 lives in West Africa this year poses a serious, ongoing threat to that region: the spread to capital cities and Nigeria-Africa's most populous nation-presents new challenges for healthcare professionals.

15 Aug 2014

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors.

15 Aug 2014

Scientists identify gene that regulates sleep and wake rhythms

Scientists at the Salk Institute for Biological Studies have identified a gene that regulates sleep and wake rhythms.

14 Aug 2014

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.

14 Aug 2014

Research and planning to meet health needs of people living with HIV

As effective treatments for HIV become more widely available in low- and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV.

14 Aug 2014

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy.

13 Aug 2014

High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine.

13 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases.

13 Aug 2014

Canadian government to donate experimental vaccine to combat Ebola virus

The Honourable Rona Ambrose, Minister of Health, today announced that the Government of Canada will donate doses of an experimental Ebola vaccine developed by the Public Health Agency of Canada to the World Health Organization (WHO) in its role as an international coordinating body in responding to the ongoing Ebola outbreak in West Africa.

13 Aug 2014

Lung-damaging bacterium turns body's antibody response in its favor

A lung-damaging bacterium turns the body's antibody response in its favor, according to a study published in The Journal of Experimental Medicine.

13 Aug 2014

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide.

12 Aug 2014

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria.

12 Aug 2014

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics.

12 Aug 2014

GW researcher awarded grant to develop a model system to study PN infection

According to a recent World Health Organization report of the leading causes of death worldwide, one-third of all deaths are due to infectious and parasitic diseases. There are currently no vaccines for parasitic nematode (PN), or worm infections in humans, and development of new drugs and vaccines will stall until researchers have a better understanding of PN biology.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014